vs

Side-by-side financial comparison of Aquestive Therapeutics, Inc. (AQST) and RIVERVIEW BANCORP INC (RVSB). Click either name above to swap in a different company.

RIVERVIEW BANCORP INC is the larger business by last-quarter revenue ($14.0M vs $13.0M, roughly 1.1× Aquestive Therapeutics, Inc.). RIVERVIEW BANCORP INC runs the higher net margin — 9.8% vs -244.8%, a 254.6% gap on every dollar of revenue. On growth, RIVERVIEW BANCORP INC posted the faster year-over-year revenue change (10.4% vs 9.7%). RIVERVIEW BANCORP INC produced more free cash flow last quarter ($-736.0K vs $-8.6M). Over the past eight quarters, RIVERVIEW BANCORP INC's revenue compounded faster (24.6% CAGR vs 3.9%).

Aquestive Therapeutics is a specialty pharmaceutical company focused on developing and commercializing innovative treatments for central nervous system disorders. It leverages proprietary drug delivery technologies to create accessible, patient-friendly therapeutic options, serving healthcare providers and patients across North America and European markets, with core offerings addressing unmet needs in neurology and psychiatry.

Riverview Bancorp Inc. is a U.S.-based bank holding company operating Riverview Community Bank, primarily serving the Pacific Northwest region. It offers personal and commercial banking products including savings accounts, consumer loans, mortgages, commercial lending, and small business financial solutions for retail customers and local enterprises.

AQST vs RVSB — Head-to-Head

Bigger by revenue
RVSB
RVSB
1.1× larger
RVSB
$14.0M
$13.0M
AQST
Growing faster (revenue YoY)
RVSB
RVSB
+0.7% gap
RVSB
10.4%
9.7%
AQST
Higher net margin
RVSB
RVSB
254.6% more per $
RVSB
9.8%
-244.8%
AQST
More free cash flow
RVSB
RVSB
$7.8M more FCF
RVSB
$-736.0K
$-8.6M
AQST
Faster 2-yr revenue CAGR
RVSB
RVSB
Annualised
RVSB
24.6%
3.9%
AQST

Income Statement — Q4 FY2025 vs Q3 FY2026

Metric
AQST
AQST
RVSB
RVSB
Revenue
$13.0M
$14.0M
Net Profit
$-31.9M
$1.4M
Gross Margin
55.2%
Operating Margin
-221.6%
12.4%
Net Margin
-244.8%
9.8%
Revenue YoY
9.7%
10.4%
Net Profit YoY
-86.8%
11.8%
EPS (diluted)
$-0.26
$0.07

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AQST
AQST
RVSB
RVSB
Q4 25
$13.0M
$14.0M
Q3 25
$12.8M
$13.6M
Q2 25
$10.0M
$13.3M
Q1 25
$8.7M
$12.9M
Q4 24
$11.9M
$12.7M
Q3 24
$13.5M
$12.8M
Q2 24
$20.1M
$12.2M
Q1 24
$12.1M
$9.0M
Net Profit
AQST
AQST
RVSB
RVSB
Q4 25
$-31.9M
$1.4M
Q3 25
$-15.4M
$1.1M
Q2 25
$-13.5M
$1.2M
Q1 25
$-22.9M
$1.1M
Q4 24
$-17.1M
$1.2M
Q3 24
$-11.5M
$1.6M
Q2 24
$-2.7M
$966.0K
Q1 24
$-12.8M
$-3.0M
Gross Margin
AQST
AQST
RVSB
RVSB
Q4 25
55.2%
Q3 25
64.8%
Q2 25
54.4%
Q1 25
58.1%
Q4 24
61.9%
Q3 24
67.2%
Q2 24
77.5%
Q1 24
63.6%
Operating Margin
AQST
AQST
RVSB
RVSB
Q4 25
-221.6%
12.4%
Q3 25
-89.6%
10.2%
Q2 25
-113.6%
11.7%
Q1 25
-222.1%
11.3%
Q4 24
-114.4%
12.4%
Q3 24
-61.2%
15.5%
Q2 24
0.3%
10.0%
Q1 24
-74.3%
-47.5%
Net Margin
AQST
AQST
RVSB
RVSB
Q4 25
-244.8%
9.8%
Q3 25
-120.6%
8.1%
Q2 25
-135.4%
9.2%
Q1 25
-263.0%
8.9%
Q4 24
-143.7%
9.7%
Q3 24
-85.0%
12.2%
Q2 24
-13.7%
7.9%
Q1 24
-106.4%
-34.7%
EPS (diluted)
AQST
AQST
RVSB
RVSB
Q4 25
$-0.26
$0.07
Q3 25
$-0.14
$0.05
Q2 25
$-0.14
$0.06
Q1 25
$-0.24
$0.05
Q4 24
$-0.18
$0.06
Q3 24
$-0.13
$0.07
Q2 24
$-0.03
$0.05
Q1 24
$-0.17
$-0.14

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AQST
AQST
RVSB
RVSB
Cash + ST InvestmentsLiquidity on hand
$28.6M
Total DebtLower is stronger
$27.5M
Stockholders' EquityBook value
$-33.7M
$164.2M
Total Assets
$160.4M
$1.5B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AQST
AQST
RVSB
RVSB
Q4 25
$28.6M
Q3 25
$129.1M
$32.8M
Q2 25
$60.5M
$34.2M
Q1 25
$68.7M
$29.4M
Q4 24
$71.5M
$25.3M
Q3 24
$77.9M
$31.0M
Q2 24
$89.9M
$27.8M
Q1 24
$95.2M
$23.6M
Total Debt
AQST
AQST
RVSB
RVSB
Q4 25
$27.5M
Q3 25
$45.0M
Q2 25
$45.0M
Q1 25
$45.0M
Q4 24
$32.5M
Q3 24
$45.0M
Q2 24
$45.0M
Q1 24
$45.0M
Stockholders' Equity
AQST
AQST
RVSB
RVSB
Q4 25
$-33.7M
$164.2M
Q3 25
$-4.1M
$163.5M
Q2 25
$-72.6M
$162.0M
Q1 25
$-60.9M
$160.0M
Q4 24
$-60.2M
$158.3M
Q3 24
$-45.4M
$160.8M
Q2 24
$-35.5M
$155.9M
Q1 24
$-36.3M
$155.6M
Total Assets
AQST
AQST
RVSB
RVSB
Q4 25
$160.4M
$1.5B
Q3 25
$163.6M
$1.5B
Q2 25
$93.7M
$1.5B
Q1 25
$102.2M
$1.5B
Q4 24
$101.4M
$1.5B
Q3 24
$110.0M
$1.5B
Q2 24
$117.6M
$1.5B
Q1 24
$129.5M
$1.5B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AQST
AQST
RVSB
RVSB
Operating Cash FlowLast quarter
$-8.5M
$-506.0K
Free Cash FlowOCF − Capex
$-8.6M
$-736.0K
FCF MarginFCF / Revenue
-65.7%
-5.2%
Capex IntensityCapex / Revenue
0.7%
1.6%
Cash ConversionOCF / Net Profit
-0.37×
TTM Free Cash FlowTrailing 4 quarters
$-53.0M
$20.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AQST
AQST
RVSB
RVSB
Q4 25
$-8.5M
$-506.0K
Q3 25
$-12.6M
$16.8M
Q2 25
$-7.9M
$-697.0K
Q1 25
$-23.4M
$8.3M
Q4 24
$-6.5M
$2.2M
Q3 24
$-11.9M
$764.0K
Q2 24
$-7.0M
$5.4M
Q1 24
$-10.4M
$12.8M
Free Cash Flow
AQST
AQST
RVSB
RVSB
Q4 25
$-8.6M
$-736.0K
Q3 25
$-12.9M
$16.4M
Q2 25
$-8.0M
$-773.0K
Q1 25
$-23.5M
$5.6M
Q4 24
$-6.5M
$1.9M
Q3 24
$-12.0M
$-1.4M
Q2 24
$-7.0M
$5.3M
Q1 24
$-10.4M
$7.1M
FCF Margin
AQST
AQST
RVSB
RVSB
Q4 25
-65.7%
-5.2%
Q3 25
-100.6%
120.1%
Q2 25
-80.2%
-5.8%
Q1 25
-269.9%
43.1%
Q4 24
-54.8%
15.0%
Q3 24
-88.3%
-11.3%
Q2 24
-35.0%
43.7%
Q1 24
-86.4%
79.0%
Capex Intensity
AQST
AQST
RVSB
RVSB
Q4 25
0.7%
1.6%
Q3 25
1.8%
2.9%
Q2 25
1.1%
0.6%
Q1 25
1.5%
21.0%
Q4 24
0.1%
2.4%
Q3 24
0.6%
17.3%
Q2 24
0.2%
0.9%
Q1 24
0.2%
62.0%
Cash Conversion
AQST
AQST
RVSB
RVSB
Q4 25
-0.37×
Q3 25
15.25×
Q2 25
-0.57×
Q1 25
7.20×
Q4 24
1.79×
Q3 24
0.49×
Q2 24
5.63×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons